Truncating, in biology and genetics, means cutting a protein short so it’s missing part of its normal structure. This happens when a mutation in DNA creates a premature “stop” signal, telling the cell to halt protein production before the job is finished. The result is a shortened, often nonfunctional protein that can cause serious disease. Outside of genetics, truncating simply means shortening or cutting off part of something, whether that’s rounding down a number in math or trimming data in computing. But in medicine and science, truncating most often refers to what happens when genes produce incomplete proteins.
How a Truncating Mutation Works
Your DNA contains instructions for building proteins, and those instructions are read in a specific sequence from start to finish. A truncating mutation inserts a premature stop signal somewhere in that sequence. The cell’s protein-building machinery hits this false stop sign and quits early, producing a protein that’s missing everything downstream of the error. These shortened proteins are called truncated proteins.
Two main types of mutations cause this. A nonsense mutation swaps a single DNA letter, turning a normal instruction into a stop signal. A frameshift mutation inserts or deletes one or more DNA letters, which throws off the entire reading sequence, like removing a letter from a sentence and running all the remaining words together. Frameshifts almost always create a premature stop signal somewhere in the garbled sequence that follows. Both types lead to the same outcome: a protein that’s too short to work properly.
What Happens to Truncated Proteins
Cells have a built-in quality control system for catching these errors. A surveillance pathway detects the premature stop signal in the genetic message and flags it for destruction before the truncated protein can even be made in large quantities. This cleanup process breaks down the faulty genetic message, preventing the accumulation of incomplete proteins that could be toxic or interfere with normal cell function.
This quality control system doesn’t catch everything, though. Some truncated messages slip through, and when they do, the shortened proteins they produce typically lose function. A protein missing its last third, for example, may lack the region it needs to bind to other molecules, carry out its chemical reaction, or anchor itself in the right location within the cell. In some cases, truncated proteins don’t just fail to work. They actively interfere with the normal copies, creating a dominant negative effect that makes things worse than simply having less protein.
A large study of over 337,000 people in the UK Biobank found that protein-truncating variants most often cause loss of protein function, though gain-of-function effects are also possible. One example: a truncating variant in a gene called GSDMB removes a key section of the protein and eliminates its ability to trigger cell death, which actually protects carriers against asthma.
Truncating Mutations and Disease
Many genetic diseases trace back to truncating mutations. One of the clearest examples is the difference between Duchenne and Becker muscular dystrophy. Both involve the same gene, which encodes a large structural protein in muscle cells called dystrophin. In Duchenne muscular dystrophy, a nonsense or frameshift mutation truncates the protein so severely that it’s essentially absent. Boys with Duchenne typically lose the ability to walk by their early teens. In Becker muscular dystrophy, the mutation is “in-frame,” meaning it shortens the protein but preserves its basic structure. The result is a partially functional protein and a much milder disease course.
Research on the dystrophin gene has shown that even a small amount of functional protein makes a significant difference. When cells can skip over the damaged section of the gene and still produce a shortened but structured protein, as little as 5% of normal production at the cell surface correlates with milder symptoms. This finding has driven an entire class of therapies aimed at coaxing cells to skip problematic exons.
Truncation That’s Supposed to Happen
Not all protein truncation is harmful. Cells deliberately cut proteins shorter as part of normal biology through a process called proteolytic processing. Enzymes called proteases snip specific bonds in a protein chain to activate it, relocate it, or change what it does. This is irreversible and highly targeted.
Signal peptides are a common example. Many proteins are built with a short leading sequence that acts like an address label, directing the protein to the right compartment in the cell. Once the protein arrives, that leading sequence gets clipped off. Hormones and immune signaling molecules are often produced as longer, inactive precursors that only become active after a protease trims them down. Viruses exploit the same principle, producing one long protein chain that gets cut into multiple functional pieces.
How Truncating Variants Are Classified
When genetic testing finds a truncating variant in a patient’s DNA, labs follow standardized guidelines to determine whether it’s disease-causing. The American College of Medical Genetics and Genomics classifies truncating variants (nonsense, frameshift, and certain splice site changes) as having “very strong evidence of pathogenicity” when they occur in a gene where loss of function is a known cause of disease.
Several caveats apply. Truncating variants near the very end of a gene may not matter much, because the protein is nearly complete by the time the premature stop hits. Variants in the last exon or near the end of the second-to-last exon are less likely to trigger the cell’s quality control system, meaning a near-full-length but slightly altered protein gets produced. Labs also check whether loss of function in that specific gene actually causes disease. In some genes, only specific types of mutations (like those that change a single amino acid) cause problems, and losing the protein entirely is tolerated.
Therapies That Override the Stop Signal
Because so many diseases stem from premature stop signals, researchers have developed drugs that try to force the cell’s protein-building machinery to read through the stop and keep going. The goal is to insert an amino acid where the stop signal sits, allowing a full-length or near-full-length protein to be produced.
Aminoglycoside antibiotics were the first compounds found to do this. They bind to the part of the ribosome (the cell’s protein assembly machine) that checks whether each genetic instruction matches the right building block. By loosening that quality check, aminoglycosides can cause the ribosome to slip an amino acid in at a premature stop codon instead of halting. The amino acid won’t necessarily be the “correct” one, but the resulting protein is often functional enough to provide benefit.
A newer drug called ataluren was specifically designed to suppress premature stop codons in human cells without affecting the normal stop signals that mark the true end of a protein. This selectivity matters: you want to override the false stops caused by mutations without disrupting the thousands of legitimate stop signals the cell depends on every day. Ataluren has been studied in conditions like Duchenne muscular dystrophy and cystic fibrosis, both of which can be caused by nonsense mutations.